<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039558</url>
  </required_header>
  <id_info>
    <org_study_id>RECURRENT GERD</org_study_id>
    <nct_id>NCT01039558</nct_id>
  </id_info>
  <brief_title>The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate the Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will estimate the responses of lansoprazole and ecabet sodium combination therapy and
      compare with lansoprazole and placebo therapy in patients who need additional therapy after
      standard proton pump inhibitor treatment for 4week or more in recurrent gastroesophageal
      reflux disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>We will compare the summations of symptoms score and calculate the response rate</measure>
    <time_frame>after 4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the global response of treatment</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>lansoprazole + ecabet sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lansoprazole + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ecabet sodium</intervention_name>
    <description>Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.</description>
    <arm_group_label>lansoprazole + ecabet sodium</arm_group_label>
    <other_name>Gastrex ganules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.</description>
    <arm_group_label>lansoprazole + ecabet sodium</arm_group_label>
    <arm_group_label>lansoprazole + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.</description>
    <arm_group_label>lansoprazole + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 19-75 years

          -  patients with typical gastroesophageal symptom or erosive reflux esophagitis on
             gastroduodenoscopy

          -  patients with recurrent gastroesophageal symptom after standard proton pump inhibitor
             treatment for 4 weeks or more

        Exclusion Criteria:

          -  patients with gastric ulcer or duodenal ulcer

          -  patients with gastric cancer or esophageal cancer

          -  pregnant or postpartum women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Sung Kim, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>July 27, 2011</last_update_submitted>
  <last_update_submitted_qc>July 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joo Sung Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>lansoprazole</keyword>
  <keyword>ecabet sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Ecabet</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

